Question | Discussion | References | CME Credit

Case 7: References

  1. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002;22:930-3.
    [The following link will open in a new window. PubMed Abstract]
  2. Lochet P, Peyrière H, Lotthé A, Mauboussin JM, Delmas B, Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Med. 2003;4:62-6.
    [The following link will open in a new window. PubMed Abstract]
  3. Moreno A, Labelle C, Samet JH. Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases. HIV Med. 2003;4:302-4.
    [The following link will open in a new window. PubMed Abstract]
  4. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y; TRT-5 Group. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care. 2004;16:558-64.
    [The following link will open in a new window. PubMed Abstract]
  5. Fumaz CR, Muñoz-Moreno JA, Moltó J, et al. Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr. 2005;38:560-5.
    [The following link will open in a new window. PubMed Abstract]
  6. Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, Martín-Hidalgo A. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41:1648-53.
    [The following link will open in a new window. PubMed Abstract]
  7. Hawkins T, Geist C, Young B, Giblin A, Mercier RC, Thornton K, Haubrich R. Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. HIV Clin Trials. 2005;6:187-96.
    [The following link will open in a new window. PubMed Abstract]
  8. Rihs TA, Begley K, Smith DE, et al. Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med. 2006;7:544-8.
    [The following link will open in a new window. PubMed Abstract]
  9. Moyle G, Fletcher C, Brown H, Mandalia S, Gazzard B. Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. HIV Med. 2006;7:243-7.
    [The following link will open in a new window. PubMed Abstract]
  10. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-21.
    [The following link will open in a new window. PubMed Abstract]
  11. von Giesen HJ, Köller H, de Nocker D, Haslinger BA, Arendt G. Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clin Trials. 2003;4:382-90.
    [The following link will open in a new window. PubMed Abstract]
  12. Journot V, Chene G, De Castro N, et al. Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. Clin Infect Dis. 2006;42:1790-9.
    [The following link will open in a new window. PubMed Abstract]
  13. Arendt G, de Nocker D, von Giesen HJ, Nolting T. Neuropsychiatric side effects of efavirenz therapy. Expert Opin Drug Saf. 2007;6:147-54.
    [The following link will open in a new window. PubMed Abstract]
  14. Peyriere H, Mauboussin JM, Rouanet I, Fabre J, Reynes J, Hillaire-Buys D. Management of sudden psychiatric disorders related to efavirenz. AIDS. 2001;15:1323-4.
    [The following link will open in a new window. PubMed Abstract]
  15. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-5.
    [The following link will open in a new window. PubMed Abstract]
  16. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-400.
    [The following link will open in a new window. PubMed Abstract]
  17. Kappelhoff BS, van Leth F, Robinson PA, et al. Are adverse events of nevirapine and efavirenz related to plasma concentrations? Antivir Ther. 2005;10:489-98.
    [The following link will open in a new window. PubMed Abstract]
  18. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
    [The following link will open in a new window. PubMed Abstract]
  19. Van Luin M, Bannister WP, Mocroft A, et al. Discontinuation of efavirenz and ethnicity, a EuroSIDA PK study. 9th International Workshop on Clinical Pharmacology of HIV Therapy. 7-9 April 2008. New Orleans. Abstract P51.
  20. Boly L, Cafaro V, Dyner T. Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. J Acquir Immune Defic Syndr. 2006;42:514-5.
    [The following link will open in a new window. PubMed Abstract]
  21. Clarke SM, Mulcahy FM. Efavirenz therapy in drug users. HIV Med. 2000;1 Suppl 1:15-7.
    [The following link will open in a new window. PubMed Abstract]
  22. Juethner SN, Seyfried W, Aberg JA. Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. HIV Clin Trials. 2003;4:145-9.
    [The following link will open in a new window. PubMed Abstract]
  23. Faggian F, Lattuada E, Lanzafame M, Antolini D, Concia E, Vento S. Recreational substance use and tolerance of efavirenz in HIV-1 infected patients. AIDS Care. 2005;17:908-10.
    [The following link will open in a new window. PubMed Abstract]

[Back to Case 7 Question | Back to Discussion]

CME Credit | Back to Top